Remo Panaccione, MD

University of Calgary, Canada

Poster(s):

• P4377 - Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4378 - European and U.S. Patient and Health Care Professional Perspectives on the Experience of Fatigue in Crohn’s Disease and Ulcerative Colitis: Communicating Needs and Features of IBD Experiences (CONFIDE) Survey
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4379 - Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE)
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET

• P4380 - Burden and Impact of Fatigue on Patients with Crohn’s Disease and Ulcerative Colitis in the United States and Europe: Results from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET